This study also provides a potential therapeutic approach using SnMP, a drug that has already been used in the clinic46,47, to target the ability of FAP+ HO-1+ TAMs to facilitate tumour cell intravasation and spread of the disease (Fig. 7). Here, FAP is linked to neoplasm.